27 results
8-K
EX-99.1
PRME
Prime Medicine Inc
1 Mar 24
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
8:01am
our existing work, enable us to pursue additional programs, and provide access to innovation that can further advance Prime Editing. Over time, we
8-K
EX-99.1
PRME
Prime Medicine Inc
8 Jan 24
Regulation FD Disclosure
8:01am
and platform Preparation for late-stage Executed on key early hires to innovation capabilities product development of lead build out and scale … is Entering the Clinic at the Right Time: Evolving Landscape Favors Innovation in Cell and Gene Therapy Positive regulatory interactions in U.S
8-K
EX-99.2
PRME
Prime Medicine Inc
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
of investors Leveraging close relationship with founders David Liu and Andrew Anzalone to bring new innovation rapidly into Prime Medicine Aim to create
10-Q
om0n1aiqw qfril6b6
14 Nov 22
Quarterly report
4:46pm
424B4
kow0zg aoxk
21 Oct 22
Prospectus supplement with pricing info
4:47pm
S-1/A
tgimpl
13 Oct 22
IPO registration (amended)
10:51am
S-1
9qmlux5 loqofqp027
23 Sep 22
IPO registration
4:12pm
S-1
EX-10.18
tb77y748d0hzvmqg
23 Sep 22
IPO registration
4:12pm
S-1
EX-10.14
88pcxmlz27 z9yei1s
23 Sep 22
IPO registration
4:12pm
DRS/A
ymcm 8odgqvqq
5 Aug 22
Draft registration statement (amended)
12:00am
DRS/A
m4vxd5ko7o6ltrrlo
6 May 22
Draft registration statement (amended)
12:00am
DRSLTR
952a 6izkgo0qiqvb2
8 Apr 22
Correspondence regarding draft registration statement
12:00am
DRS/A
hhxjb3l1 yo
8 Apr 22
Draft registration statement (amended)
12:00am
UPLOAD
zujxvso hhjstbco
30 Mar 22
Letter from SEC
12:00am
DRSLTR
8kh 9pd26j5wz
25 Mar 22
Correspondence regarding draft registration statement
12:00am
DRS/A
q4fp5pkxu0
25 Mar 22
Draft registration statement (amended)
12:00am
UPLOAD
3jpo751h ud16o
15 Mar 22
Letter from SEC
12:00am